Use cases
Use cases
Knowledge Graphs
Build better knowledge graphs with millions of novel high quality cause-and-effect relationships and contextual data
MoA & Explainability
Novel evidence to explain diseases and hypothesise treatment approaches
Biomarker Selection
Identify novel pharmacodynamic biomarkers from > 40 million documents
Target Selection
Infer drug-target-disease cause-and-effect relationships to ID novel targets and validate existing hypotheses
Indication Expansion
Use data annotations to identify diseases directly connected to a target based on well-established literature evidence
Knowledge Reviews
Systematically retrieve all relevant information to support go/no-go decisions
Solutions
Solutions
Galactic Enterprise
The first fully LLM-native pipeline
Data scientists
The most novel knowledge graph of rich, unique data
Biologists
Novel targets and never-before-seen biological research evidence
Information Managers
The forefront of federated architecture and GenAI
Company
Resources
Resources
News
Insights and blog posts
Events
Upcoming conferences
Downloads
Datasheets and other resources
Webinars
Live events and recordings
Knowledge Graphs in Drug Discovery
Virtual conference series
Galactic Web login
Request demo
Galactic Web login
Request demo
News
Galactic Data 3.0: The Future of AI for R&D?
Galactic Data 3.0: The Future of AI for R&D?
Biorelate
October 30, 2025
•
5 min read
Share this post
Biorelate News
Latest News
Discover new insights and updates for data science in biopharma
View all
Galactic Data 3.0: The Future of AI for R&D?
Biorelate announces the release of Galactic Data 3.0.
Accelerating drug discovery innovation via advanced data science solutions – a case study of Almirall (global pharma company) and Biorelate (data science solutions provider)
Pharma Almirall enlisted Biorelate, with its cutting-edge AI platform, Galactic AI™, to help accelerate their R&D innovation and productivity.
Unlocking the Power of Data in AI-Driven Drug Discovery
To unlock the true potential of Artificial Intelligence, pharma companies must adopt a robust data strategy, generating and harmonising data specifically for AI applications
View all
